Paper Details

  1. Home
  2. Paper Details

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Author: , AkarcaUlus S, CakalogluYilmaz, GerkenGuido, HansenBettina, JanssenHarry L A, NiestersHubert G M, SchalmSolko W, SenturkHakan, SimonChristopher, SoThomas M K, ZeuzemStefan, ZondervanPieter, de ManRobert A, van ZonneveldMonika

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pegylated interferon alfa-2b is effective for HBeAg-positive chronic hepatitis B. Combination with lamivudine in the regimen used is not superior to monotherapy. HBV genotype is an important predictor of response to treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response. METHODS: 307 HBeAg-positive patients with chronic hepatitis B wer...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(05)17701-0

データ提供：米国国立医学図書館（NLM）

Combating Hepatitis B: Pegylated Interferon Alfa-2b and Lamivudine

Hepatitis B, a viral infection that can lead to serious liver damage, is a global health concern. This research investigates the effectiveness of pegylated interferon alfa-2b, an immunomodulatory drug, alone and in combination with lamivudine, an antiviral drug, for treating HBeAg-positive chronic hepatitis B. The study utilizes a randomized trial to compare the efficacy of these two treatment regimens. The findings provide valuable insights into the optimal treatment strategies for HBeAg-positive chronic hepatitis B, a challenging condition to manage.

Understanding Treatment Response: A Complex Landscape

The study found that pegylated interferon alfa-2b was effective for treating HBeAg-positive chronic hepatitis B, but there was no significant difference in the effectiveness of monotherapy versus combination therapy. The authors also discovered that the response to treatment varied significantly based on the genotype of the hepatitis B virus, suggesting that personalized treatment approaches may be necessary to optimize treatment outcomes.

Navigating the Path to Recovery: A Tailored Approach

This research underscores the importance of tailoring treatment approaches for chronic hepatitis B. The study’s findings highlight the need for individualized care, considering factors such as the genotype of the hepatitis B virus, the patient’s individual health status, and their tolerance for potential side effects. By working closely with healthcare professionals, patients can make informed decisions about their treatment options and navigate the path to recovery.

Dr.Camel's Conclusion

The desert of hepatitis B research is vast and complex, but this study offers valuable insights into the effectiveness of pegylated interferon alfa-2b and lamivudine for treating HBeAg-positive chronic hepatitis B. The study highlights the importance of personalized treatment approaches and emphasizes the need for continued research to develop more effective and targeted therapies for this challenging disease.

Date :
  1. Date Completed 2005-02-02
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

15639293

DOI: Digital Object Identifier

10.1016/S0140-6736(05)17701-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.